Sitazan 50mg/1000mg

Description

• Sitagliptin, a DPP-4 inhibitor, enhances the activities of GLP-1 and GIP, which leads to improved glycemic control in patients with type 2 diabetes. It achieves this by reducing fasting and post-prandial blood glucose levels. On the other hand, Metformin, a guanidine derivative, possesses antimicrobial properties. It reduces glucose production by the liver, increases glucose uptake by skeletal muscle, and enhances glucose uptake and utilization by anaerobic pathways in tissues such as the kidney. Additionally, it diminishes hunger and induces weight loss in some individuals. The combination of Sitagliptin 50mg and Metformin 1000mg is typically prescribed to adults with type 2 diabetes when diet and exercise alone are not sufficient to manage blood sugar levels. It’s worth noting that this description is a simplified overview, and the actual mechanisms of action for these drugs are more intricate and are still being researched.